| abstract |
Compounds of formula (i)and pharmaceutically acceptable salts and solvates: where R1 is hydrogen, C1-6alkyl (optinally substituted by hydroxy or C1-c4alkoxy), phenyl-C1-4alkyl-, C1-6alkenyl, C1-6alkynyl; R2 is hydrogen or up to three substituents selected from halogen, NO2, CN, N3, CF3o-,CF3s-, CF3so2-, CF3CO-,C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylo-, C1-6alkylco-, C3-6cycloalkylco-, C3-6cycloalkyl-C1-4alkylo-, C3-6cycloalkyl-C1-4alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylis-, C1-6alkyiso2-, (C1-4alkyl)2SNO2-, (C1-4alkyl)NHSO2-, (C1-4alkyl)2NCO-, (C1-4alkyl)NHCO- or CONH2; or -NR5R6 where R5 is hydrogen orC1-4alkyl, and R6 is hydrogen,C1-4alkyl, formyl, -CO2C1-4alkyl or -COC1-4alkyl; or two R2 groups together form a carbocyclic ring that is saturated or unsaturated, optionally interrupted by O or NH; R3 groups and R4 groups are each independently hydrogen or C1-6alkyl and/or the two R3 groups and/or the two R4 groups together form a C3-6spiroalkyl group, provided that at least one R3 and r4 group is not hydrogen; and X is selected from hydrogen, halogen, cyano, alkyl and alkoxy, are useful in the treatment and prophylaxix of epilepsy, migraine, and other disorders. |